MARC details
000 -LEADER |
fixed length control field |
03892nam a22004937a 4500 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
140821s20142014 xxu||||| |||| 00| 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
International Standard Serial Number |
0732-183X |
040 ## - CATALOGING SOURCE |
Original cataloging agency |
Ovid MEDLINE(R) |
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
PMID |
24711552 |
245 ## - TITLE STATEMENT |
Title |
Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. |
251 ## - Source |
Source |
Journal of Clinical Oncology. 32(14):1427-36, 2014 May 10. |
252 ## - Abbreviated Source |
Abbreviated source |
J Clin Oncol. 32(14):1427-36, 2014 May 10. |
253 ## - Journal Name |
Journal name |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Year |
2014 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Manufacturer |
FY2014 |
266 ## - Date added to catalog |
Date added to catalog |
2014-08-21 |
501 ## - WITH NOTE |
Local holdings |
Available online from MWHC library: 1999 - present, Available in print through MWHC library: 1999 - 2008 |
520 ## - SUMMARY, ETC. |
Abstract |
CONCLUSION: Exemestane given for prevention has limited negative impact on menopause-specific and health-related QOL in healthy postmenopausal women at risk for breast cancer. |
520 ## - SUMMARY, ETC. |
Abstract |
PATIENTS AND METHODS: Menopause-specific and health-related QOL were assessed by using the four Menopause-Specific Quality of Life Questionnaire (MENQOL) domains and the eight Medical Outcomes Study Short Form Health Survey (SF-36) scales at baseline, 6 months, and yearly thereafter. MENQOL questionnaire completion was high (88% to 98%) in both groups at each follow-up visit. 20140821 scores for each MENQOL and SF-36 scale, calculated at each assessment time relative to baseline, were compared by using the Wilcoxon rank-sum test. Clinically important worsened QOL was defined as a MENQOL 20140821 score increase of more than 0.5 (of 8) points and an SF-36 20140821 score decrease of more than 5 (of 100) points from baseline. |
520 ## - SUMMARY, ETC. |
Abstract |
PURPOSE: Exemestane, a steroidal aromatase inhibitor, reduced invasive breast cancer incidence by 65% among 4,560 postmenopausal women randomly assigned to exemestane (25 mg per day) compared with placebo in the National Cancer Institute of Canada (NCIC) Clinical Trials Group MAP.3 (Mammary Prevention 3) trial, but effects on quality of life (QOL) were not fully described. |
520 ## - SUMMARY, ETC. |
Abstract |
RESULTS: Exemestane had small negative effects on women's self-reported vasomotor symptoms, sexual symptoms, and pain, which occurred mainly in the first 6 months to 2 years after random assignment. However, these 140821s represented only a small excess number of women being given exemestane with clinically important worsening of QOL at one time or another; specifically, 8% more in the vasomotor domain and 4% more each in the sexual domain and for pain. No other between-group differences were observed. Overall, slightly more women in the exemestane arm (32%) than in the placebo arm (28%) discontinued assigned treatment. |
546 ## - LANGUAGE NOTE |
Language note |
English |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Androstadienes/tu [Therapeutic Use] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Aromatase Inhibitors/tu [Therapeutic Use] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Breast Neoplasms/pc [Prevention & Control] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Quality of Life |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Adult |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Aged |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Aged, 80 and over |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Female |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Humans |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Middle Aged |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Postmenopause |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Questionnaires |
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
Institution |
MedStar Health Research Institute |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Journal Article |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Multicenter Study |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Randomized Controlled Trial |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Research Support, Non-U.S. Gov't |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Thayer, Debra W |
790 ## - Authors |
All authors |
Ales-Martinez JE, Brundage M, Cheung AM, Chlebowski RT, Cooke AL, Dube P, Ellard SL, Fabian CJ, Gelmon KA, Goss PE, Hendrix S, Hiltz A, Ingle JN, Johnston D, Lickley L, Maunsell E, Pater JL, Pruthi S, Pujol P, Richardson H, Rowland KM, Ruiz A, Sarto GE, Spadafora S, Thayer DW, Tu D, Wactawski-Wende J |
856 ## - ELECTRONIC LOCATION AND ACCESS |
DOI |
<a href="http://dx.doi.org/10.1200/JCO.2013.51.2483">http://dx.doi.org/10.1200/JCO.2013.51.2483</a> |
Public note |
http://dx.doi.org/10.1200/JCO.2013.51.2483 |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Koha item type |
Journal Article |
Item type description |
Article |